The overall mission of the Oncology Department is to improve cure rates for children with cancer while reducing the side effects of therapy through a coordinated program of clinical and laboratory-based research, patient care and education. We will achieve this by close collaboration between laboratory and clinical research to understand better how cancer behaves in children and young adults. We will use this knowledge to discover new and more effective therapies for childhood malignancies while minimizing the long-term effects on our patients.
Our Oncology faculty are world leaders in identifying novel drugs and treatment modalities, defining the clinical significance of recently discovered genetic abnormalities of cancer cells, understanding mechanisms of cancer development and drug resistance, and understanding and preventing late effects of therapy. We aim to share our unique clinical expertise with colleagues nationally through our many clinical trial consortia and worldwide through our partnership with St. Jude Global. The ultimate goal of our research is to ensure that every child with cancer receives curative therapy and that this therapy allows them the potential for a healthy, long-lasting life.
Dr. Julie R. Park is a pediatric hematologist-oncologist who is interested in developing and advancing new approaches to childhood cancer therapy. Dr. Park received her MD from the University of Vermont and completed residency training in pediatrics at the University of Washington. Dr. Park then completed a fellowship in pediatric hematology/oncology at the University of Washington and Fred Hutchinson Cancer Research Center.
She has been funded as a Fellow for the Leukemia Society of America at Fred Hutchinson Cancer Research Center, and an investigator on NCI and NIH grants. As a Member of the St. Jude Faculty and Chair of the Oncology Department, Dr. Park is interested in discovering the molecular and immunologic vulnerabilities of solid tumor malignancies, such as neuroblastoma, and using this information to inform clinical trials centered on novel therapies for children with relapsed or refractory high-risk tumors.
Department staff
Rebecca Gardner, MD Associate Member
Director of Cellular Therapy Integration
Meaghan Granger, MD Associate Member
Director of Oncology Clinical Medicine
In the news
From the Pediatric Cancer Genome Project and beyond, @stjuderesearch has a long history of genetic discovery. Read about the work of our scientists on the genetics of vulnerabilities, predisposition, molecular groups and data analysis. #StJudeOn
In the news
Stay up-to-date on St. Jude's ongoing effort to end childhood cancer and other catastrophic diseases: @StJudeResearch on X (formerly Twitter).
In the news
DNA isn't destiny, but genetic predispositions do underlie many cancers. St. Jude scientists have gained a nuanced understanding of cancer predisposition and are learning more to help personalize patient therapies. Learn more. #StJudeOn
In the News
Cancer is not a monolith but a landscape of diseases with different drivers. Scientists at St. Jude are leading studies on how understanding molecular groups can advance cancer care. Read about it. #StJudeOn
In the news
Studying genomics means creating big data. Scientists at St. Jude have developed numerous tools and techniques for tackling data with cutting-edge visualizations and analysis. Learn more. #StJudeOn
The Division of Cancer Predisposition promotes cutting-edge clinical, translational and basic research related to genetic predisposition to childhood cancer.
The Division of Cancer Survivorship at St. Jude Children's Research Hospital strives to improve quality of life among adult survivors of pediatric cancer.
The Division of Molecular Oncology investigates the molecular and cellular determinants that lead to tumor formation and that dictate cellular responses to cytotoxic stresses.
The Solid Tumor division develops and tests novel therapeutics for the treatment of pediatric solid tumors, particularly those at high risk of treatment failure
The Neuro-Oncology division at St. Jude works advances knowledge related to the etiology, biology, treatment, and eventually cures of brain tumors in children
Expert consensus guidelines for the prophylaxis and management of tumor lysis syndrome in the United States: Results of a modified Delphi panel
Perissinotti AJ et al. Cancer Treat Rev, 2023
Significance of e-lesions in Hodgkin lymphoma and the creation of a new consensus definition: A report from SEARCH
Bloom M, et al. Blood Adv, 2023
Prognostic and Pharmacotypic Heterogeneity of Hyperdiploidy in Childhood ALL
Lee SHR et al. J Clin Oncol, 2023
Signaling roles of platelets in skeletal muscle regeneration
Graca FA, et al. Bioessays 2023
Rituximab administration in pediatric patients with newly diagnosed acute lymphoblastic leukemia
Hoshitsuki K et al. Leukemia, 2023
Molecular classification improves therapeutic options for infants and young children with medulloblastoma
Bagchi A, et al. J. Natl Compr Canc Netw, 2023
Immune stress suppresses innate immune signaling in preleukemic precursor B-cells to provoke leukemia in predisposed mice
Isidro-Hernández M, et al. Nat Commun, 2023
Acute lymphoblastic leukemia with central nervous system involvement-Challenges in management
Suryaprakash S, Inaba H. Indian J Pediatr, 2023
High-grade glioma in infants and young children is histologically, molecularly, and clinically diverse—Results from the SJYC07 trial and institutional
Chiang, J, Bagchi A, et al. Neuro-Oncology 2023.
Effect of the tyrosine kinase inhibitors on the growth in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case-control study
